Published in Medical Letter on the CDC and FDA, January 23rd, 2005
This approval marks a significant advance in the field of wet AMD because current treatment options are limited. Each year 200,000 Americans are diagnosed with wet AMD and this number is expected to increase dramatically with the aging of our population.
"Prevent Blindness America is very pleased with the FDA approval of Macugen, because for the first time all types of wet AMD can be treated, which...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.